CoChat

Neurogenesis and Neuroinflammation in Dialogue: Mapping Gaps, Modulating Microglia, Rewiring Aging

Open access
Tanaka, Masaru · 2026 · Cells

The DOI matches its Crossref record; 394 of the 394 references it cites were found in a registry or an index.

Abstract

Background: Aging brains are shaped by a persistent dialogue between declining neurogenesis and rising neuroinflammation. Neural stem cells progressively lose regenerative capacity, while microglia and astrocytes shift toward maladaptive states that erode synaptic plasticity and cognition. This convergence defines inflammaging, a slow yet relentless process that undermines resilience. However, the field remains hampered by critical gaps: incomplete mapping of microglial heterogeneity, poorly understood epigenetic scars from inflammasome signaling, lack of longitudinal data, unclear niche-specific immune mechanisms, and uncertain cross-species relevance. This review addresses these pressing barriers, aiming to transform fragmented insights into actionable strategies. Summary: I chart how neurogenesis and neuroinflammation operate in continuous dialogue, identify five major knowledge gaps, and evaluate strategies to reprogram this interaction. Approaches include longitudinal imaging, niche-focused immunomodulation, glial subtype reprogramming, brain-penetrant inflammasome inhibitors, and CRISPR-based epigenetic editing. Each strategy is mapped against translational potential, short-term feasibility, and long-term vision, with emphasis on how mechanistic precision can guide clinical innovation. Conclusions: Here I highlight that neurogenic potential is not entirely lost with age but may be preserved or restored by tuning immune and epigenetic environments. This review proposes a roadmap for reshaping the aging brain’s fate, offering mechanistically grounded strategies to delay cognitive decline. Beyond neurology, the work underscores a broader principle: by integrating cellular plasticity with immune modulation, science edges closer to re-engineering resilience across the lifespan.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cells15010078

Cites

394 of 394 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Neurogenesis–neuroinflammation dynamics across the lifespan. (A) Young: In the healthy young dentate gyrus (DG), abundant and actively cycling neural stem cells generate newborn neurons that successfully mature and integrate into local circuits. Supportive microglia maintain a trophic environment by releasing BDNF and other growth factors, which promote stem-cell activation and neuronal differentiation [26,27,28]. Arrows indicate pro-neurogenic signaling from microglia to stem cells and forward progression from stem cells to newborn neurons. (B) Aged: In the aged DG, stem-cell activation declines and fewer newborn neurons are produced. Microglia adopt reactive phenotypes in response to extrinsic cues (DAMPs, cytokines, peripheral immune signals, metabolic stress, BBB leakage) and intrinsic programs (epigenetic priming/innate immune memory, mitochondrial dysfunction, senescence-linked remodeling), and secrete pro-inflammatory cytokines such as IL-1β that suppress neurogenesis [12,21,24,29,30]. Arrows highlight the shift from supportive trophic signals to inflammatory cues and the resulting reduction in neuronal output. BDNF, brain-derived neurotrophic factor; DG, dentate gyrus; IL-1β, interleukin-1 beta. Created in Biorender. Tanaka, M. (2026) https://BioRender.com/pjz1qcu.
Figure 1 Neurogenesis–neuroinflammation dynamics across the lifespan. (A) Young: In the healthy young dentate gyrus (DG), abundant and actively cycling neural stem cells generate newborn neurons that successfully mature and integrate into local circuits. Supportive microglia maintain a trophic environment by releasing BDNF and other growth factors, which promote stem-cell activation and neuronal differentiation [26,27,28]. Arrows indicate pro-neurogenic signaling from microglia to stem cells and forward progression from stem cells to newborn neurons. (B) Aged: In the aged DG, stem-cell activation declines and fewer newborn neurons are produced. Microglia adopt reactive phenotypes in response to extrinsic cues (DAMPs, cytokines, peripheral immune signals, metabolic stress, BBB leakage) and intrinsic programs (epigenetic priming/innate immune memory, mitochondrial dysfunction, senescence-linked remodeling), and secrete pro-inflammatory cytokines such as IL-1β that suppress neurogenesis [12,21,24,29,30]. Arrows highlight the shift from supportive trophic signals to inflammatory cues and the resulting reduction in neuronal output. BDNF, brain-derived neurotrophic factor; DG, dentate gyrus; IL-1β, interleukin-1 beta. Created in Biorender. Tanaka, M. (2026) https://BioRender.com/pjz1qcu.CC BY · PubMed Central
Figure 2 Region-specific microglial diversity and aging. (A) Hippocampus: Hippocampal microglia shift from a predominantly homeostatic profile in young animals to a primed, pro-inflammatory state with aging. This is illustrated by increased reactive microglial signatures and elevated inflammatory markers, reflecting the heightened vulnerability of the neurogenic dentate gyrus (DG). The upward arrow indicates an age-related rise in priming and inflammatory activation [24,29,116]. (B) Cortex: Cortical microglia exhibit a mosaic, transitional aging phenotype. The heatmap summarizes relative transcriptional activities—homeostatic, lipid-associated, interferon-responsive, and DAM (disease-associated microglia) vulnerability—across young and aged states. Color gradients and the horizontal age-arrow illustrate how these signatures shift heterogeneously with age, highlighting multiple partially overlapping microglial subtypes rather than a uniform transition [47,165]. Dark blue—high homeostatic activity; Light blue—moderate homeostatic activity; Grey—lipid-associated activity; Yellow—interferon-responsive activity; Red—high DAM-vulnerability activity (C) Cerebellum: Cerebellar microglia largely preserve a stable, homeostatic phenotype across aging. Bar plots and conceptual illustrations show minimal change in activation markers, and microglia remain predominantly ramified with limited shift toward inflammatory states [166,167]. Overall interpretation: Microglial aging is regionally diverse. Hippocampal microglia tend toward primed, pro-inflammatory profiles; cortical microglia adopt mixed and transitional states; and cerebellar microglia maintain homeostability. This heterogeneity reveals that aging does not uniformly reprogram microglia across the brain and underscores the need for spatially tailored therapeutic strategies targeting region-specific vulnerabilities. DAM, disease-associated microglia. Created in Biorender. Tanaka, M. (2026) https://BioRender.com/vu0jdxr.
Figure 2 Region-specific microglial diversity and aging. (A) Hippocampus: Hippocampal microglia shift from a predominantly homeostatic profile in young animals to a primed, pro-inflammatory state with aging. This is illustrated by increased reactive microglial signatures and elevated inflammatory markers, reflecting the heightened vulnerability of the neurogenic dentate gyrus (DG). The upward arrow indicates an age-related rise in priming and inflammatory activation [24,29,116]. (B) Cortex: Cortical microglia exhibit a mosaic, transitional aging phenotype. The heatmap summarizes relative transcriptional activities—homeostatic, lipid-associated, interferon-responsive, and DAM (disease-associated microglia) vulnerability—across young and aged states. Color gradients and the horizontal age-arrow illustrate how these signatures shift heterogeneously with age, highlighting multiple partially overlapping microglial subtypes rather than a uniform transition [47,165]. Dark blue—high homeostatic activity; Light blue—moderate homeostatic activity; Grey—lipid-associated activity; Yellow—interferon-responsive activity; Red—high DAM-vulnerability activity (C) Cerebellum: Cerebellar microglia largely preserve a stable, homeostatic phenotype across aging. Bar plots and conceptual illustrations show minimal change in activation markers, and microglia remain predominantly ramified with limited shift toward inflammatory states [166,167]. Overall interpretation: Microglial aging is regionally diverse. Hippocampal microglia tend toward primed, pro-inflammatory profiles; cortical microglia adopt mixed and transitional states; and cerebellar microglia maintain homeostability. This heterogeneity reveals that aging does not uniformly reprogram microglia across the brain and underscores the need for spatially tailored therapeutic strategies targeting region-specific vulnerabilities. DAM, disease-associated microglia. Created in Biorender. Tanaka, M. (2026) https://BioRender.com/vu0jdxr.CC BY · PubMed Central
Figure 3 Neuroimmune interventions—from mechanism to therapeutic direction. (A) Imaging: Depicts neuroimmune mapping tools used for diagnostic and analytical purposes. The bullets refer to: Neuroimmune mapping—visualization of microglial and inflammatory states; In vivo monitoring—longitudinal tracking of neurogenic and neuroimmune changes; Functional scans—PET/MRI measures linking immune activity to neurogenic output. These modalities assess, rather than modify, biological pathways [216,217,218]. (B) Immunomodulation: Illustrates strategies that recalibrate maladaptive immune activity. The bullets indicate: Signal tuning—adjusting microglial or cytokine signaling thresholds; Immune recalibration—restoring balanced immune tone; Cytokine control—targeted modulation of IL-1β, TNF, IL-6, or related mediators [24,29]. (C) Glial Reprogramming: Represents approaches that shift glial cell identity or function. Bullets correspond to: Phenotype shift—moving microglia or astrocytes into supportive states; Lineage conversion—direct astrocyte-to-neuron or glia-to-neuron reprogramming; Glial remodeling—restructuring glial networks to enhance neurogenesis [192,219,220]. (D) NLRP3 Inhibition: Highlights suppression of inflammasome-mediated inflammation. Bullets denote: Inflammasome block—direct inhibition of NLRP3 assembly/activation; IL-1β suppression—reduction in downstream pro-inflammatory cytokine release; Danger-signal arrest—prevention of upstream triggers driving chronic activation [221,222,223,224,225,226]. (E) Epigenetic Editing Shows locus-specific chromatin tuning tools. The bullets signify: Chromatin tuning—modifying histone or DNA accessibility at inflammatory loci; Gene correction—targeted suppression or activation of disease-relevant genes; Locus rewriting—durable transcriptional reprogramming without DNA cleavage [227,228,229,230,231,232]. This figure provides a modular overview of five neuroimmune intervention strategies spanning monitoring, immune recalibration, glial engineering, inflammasome blockade, and epigenomic control. Together, they outline mechanistic entry points for preserving or restoring adult neurogenesis. Imaging modalities function strictly as diagnostic and analytical tools rather than interventions, supporting evaluation of therapeutic effects on neurogenic and inflammatory dynamics. IL-1β, interleukin-1 beta; NLPR3, NLR family pyrin domain containing 3. Created in BioRender. Tanaka, M. (2026) https://BioRender.com/073ljub.
Figure 3 Neuroimmune interventions—from mechanism to therapeutic direction. (A) Imaging: Depicts neuroimmune mapping tools used for diagnostic and analytical purposes. The bullets refer to: Neuroimmune mapping—visualization of microglial and inflammatory states; In vivo monitoring—longitudinal tracking of neurogenic and neuroimmune changes; Functional scans—PET/MRI measures linking immune activity to neurogenic output. These modalities assess, rather than modify, biological pathways [216,217,218]. (B) Immunomodulation: Illustrates strategies that recalibrate maladaptive immune activity. The bullets indicate: Signal tuning—adjusting microglial or cytokine signaling thresholds; Immune recalibration—restoring balanced immune tone; Cytokine control—targeted modulation of IL-1β, TNF, IL-6, or related mediators [24,29]. (C) Glial Reprogramming: Represents approaches that shift glial cell identity or function. Bullets correspond to: Phenotype shift—moving microglia or astrocytes into supportive states; Lineage conversion—direct astrocyte-to-neuron or glia-to-neuron reprogramming; Glial remodeling—restructuring glial networks to enhance neurogenesis [192,219,220]. (D) NLRP3 Inhibition: Highlights suppression of inflammasome-mediated inflammation. Bullets denote: Inflammasome block—direct inhibition of NLRP3 assembly/activation; IL-1β suppression—reduction in downstream pro-inflammatory cytokine release; Danger-signal arrest—prevention of upstream triggers driving chronic activation [221,222,223,224,225,226]. (E) Epigenetic Editing Shows locus-specific chromatin tuning tools. The bullets signify: Chromatin tuning—modifying histone or DNA accessibility at inflammatory loci; Gene correction—targeted suppression or activation of disease-relevant genes; Locus rewriting—durable transcriptional reprogramming without DNA cleavage [227,228,229,230,231,232]. This figure provides a modular overview of five neuroimmune intervention strategies spanning monitoring, immune recalibration, glial engineering, inflammasome blockade, and epigenomic control. Together, they outline mechanistic entry points for preserving or restoring adult neurogenesis. Imaging modalities function strictly as diagnostic and analytical tools rather than interventions, supporting evaluation of therapeutic effects on neurogenic and inflammatory dynamics. IL-1β, interleukin-1 beta; NLPR3, NLR family pyrin domain containing 3. Created in BioRender. Tanaka, M. (2026) https://BioRender.com/073ljub.CC BY · PubMed Central
Figure 4 Comparative overview of neurogenic capacity in rodents and humans. Cross-species comparisons are complicated by age-matching and sampling context: many rodent datasets derive from young adult animals, whereas human evidence often relies on post-mortem tissue from older individuals with variable comorbidity and peri-mortem factors. Accordingly, the schematic emphasizes directional trends and methodological uncertainty, not direct quantitative equivalence of neurogenic ‘capacity’ between species. (A) Rodent Brain: Rodents maintain relatively high levels of adult neurogenesis across the lifespan, supported by diverse microglial populations and sustained subventricular zone (SVZ) neurogenic activity. This includes robust DG and SVZ neurogenesis in young adulthood and measurable persistence into aging, consistent with preclinical neurogenic literature [1,2,3]. Rodent microglia show increased phenotypic diversity and clear age-associated priming [116,165]. Survival curves illustrate the well-documented gradual decline in neuronal persistence with age, while maintaining observable neurogenic capacity. (B) Human Brain: Humans exhibit markedly reduced adult neurogenesis, diminished microglial diversity, and limited or absent SVZ-derived neuronal production. Human studies report much lower baseline neurogenic output, debated persistence in older age groups, and restricted microglial heterogeneity compared with rodents [1,2]. Human microglial transcriptional profiles also show less diverse aging trajectories relative to rodent profiles [304]. The survival curve reflects minimal or near-zero long-term survival of adult-born neurons across adulthood. Translational potential & interventional strategies: The lower panel highlights mechanistic targets and candidate interventions with therapeutic relevance. Inflammasome priming inhibitors: Supported by preclinical NLRP3-blocking agents such as NT-0796, MCC950, BGE-102 [221,222,223,224,226] for longitudinal neuroimmune monitoring: FLT-PET, TSPO-PET, and hybrid PET/MRI [216,217,250]. Exercise-driven neurogenic enhancement: Rodent and translational exercise effects on neurogenesis and inflammatory pathways [301]. Targeted immunopharmacology: Cytokine-level immunomodulation from IL-1β/TNF-driven models [24,29]. Gene-editing platforms: CRISPR-based epigenetic or transcriptional tuning tools [227,229,230,231,232]. SVZ, subventricular zone. Created in BioRender. Tanaka, M. (2026) https://BioRender.com/eqw4kap.
Figure 4 Comparative overview of neurogenic capacity in rodents and humans. Cross-species comparisons are complicated by age-matching and sampling context: many rodent datasets derive from young adult animals, whereas human evidence often relies on post-mortem tissue from older individuals with variable comorbidity and peri-mortem factors. Accordingly, the schematic emphasizes directional trends and methodological uncertainty, not direct quantitative equivalence of neurogenic ‘capacity’ between species. (A) Rodent Brain: Rodents maintain relatively high levels of adult neurogenesis across the lifespan, supported by diverse microglial populations and sustained subventricular zone (SVZ) neurogenic activity. This includes robust DG and SVZ neurogenesis in young adulthood and measurable persistence into aging, consistent with preclinical neurogenic literature [1,2,3]. Rodent microglia show increased phenotypic diversity and clear age-associated priming [116,165]. Survival curves illustrate the well-documented gradual decline in neuronal persistence with age, while maintaining observable neurogenic capacity. (B) Human Brain: Humans exhibit markedly reduced adult neurogenesis, diminished microglial diversity, and limited or absent SVZ-derived neuronal production. Human studies report much lower baseline neurogenic output, debated persistence in older age groups, and restricted microglial heterogeneity compared with rodents [1,2]. Human microglial transcriptional profiles also show less diverse aging trajectories relative to rodent profiles [304]. The survival curve reflects minimal or near-zero long-term survival of adult-born neurons across adulthood. Translational potential & interventional strategies: The lower panel highlights mechanistic targets and candidate interventions with therapeutic relevance. Inflammasome priming inhibitors: Supported by preclinical NLRP3-blocking agents such as NT-0796, MCC950, BGE-102 [221,222,223,224,226] for longitudinal neuroimmune monitoring: FLT-PET, TSPO-PET, and hybrid PET/MRI [216,217,250]. Exercise-driven neurogenic enhancement: Rodent and translational exercise effects on neurogenesis and inflammatory pathways [301]. Targeted immunopharmacology: Cytokine-level immunomodulation from IL-1β/TNF-driven models [24,29]. Gene-editing platforms: CRISPR-based epigenetic or transcriptional tuning tools [227,229,230,231,232]. SVZ, subventricular zone. Created in BioRender. Tanaka, M. (2026) https://BioRender.com/eqw4kap.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Items 201–394 of 394

Research works printed but not linked: 3

  1. Gemma, 2010, Neuron-Microglia Dialogue and Hippocampal Neurogenesis in the Aged Brain, Aging Dis., 1, 232
  2. Dutta, 2021, Inferring temporal dynamics from cross-sectional data using Langevin dynamics, R. Soc. Open Sci., 8, 211374, 10.1098/rsos.211374 · DOI
  3. Kamei, 2022, In vivo Chronic Two-Photon Imaging of Microglia in the Mouse Hippocampus, J. Vis. Exp., 185, e64104

Cited by

See all 11

Metadata

Authors
Tanaka, M.
Affiliations
University of Szeged (HU)
Corresponding author
Tanaka, Masaru
Venue
Cells
Publisher
MDPI AG
Published
2026-01-03
Volume
15
Issue
1
Pages
78
ISSN
2073-4409 (ISSN-L)
OpenAlex
W7118216243
Cited by
11
References
374
Citations by year
2026: 11
FWCI
8.39
Type
journal article
Language
en
Open access
Locations
  • Cells (publishedVersion, cc-by)
  • Preprints.org (acceptedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
HUN-REN Hungarian Research Network
Topics
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Neuroscience › Developmental Neuroscience › Neurogenesis and neuroplasticity mechanisms
  • Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
Keywords
neurogenesis, neuroinflammation, brain aging, inflammaging, microglia, astrocytes, neural stem cells, microglial heterogeneity, inflammasome signaling, epigenetic regulation, glial reprogramming, immunomodulation, cognitive decline, neurodegeneration, neurogenic niche
MeSH terms
Neuroinflammatory Diseases, Aging, Animals, Brain, Humans, Inflammation, Microglia, Neurogenesis, Neural Stem Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.